SpliceCore Description
Artificial Intelligence and RNA sequencing (RNA–seq data) are both a necessity and a way to develop therapeutics that target splicing mistakes. Machine learning allows us to quickly identify new splicing mistakes and design therapeutic compounds to correct them. SpliceCore, our AI platform for RNA therapeutics research, is what we call SpliceCore. This technology platform was specifically designed for the analysis and interpretation of RNA sequencing data. It can identify, validate and test hypothetical drug targets quicker than traditional methods. Our proprietary database of over 5 million potential RNA-splicing errors is the heart of SpliceCore. It is the world's largest database of splicing mistakes and is used to test all RNA sequencing data that is submitted for analysis. Scalable cloud computing allows us to process large amounts of RNA sequencing data efficiently at a higher speed and lower cost, thereby exponentially accelerating therapeutic innovation.
SpliceCore Alternatives
SYNTHIA Retrosynthesis Software
SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules.
You can quickly and efficiently scan hundreds pathways to identify the best options for your needs.
Discover the most cost-effective route to your target molecule with the latest visualization and filtering features.
You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules.
Explore innovative and unique syntheses to build your desired molecule.
Easy to generate a list for starting materials that are commercially available for your synthesis.
ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.
Learn more
BIOiSIM
BIOiSIMTM, a revolutionary 'virtual drug engine', is the first-in-class tool that allows drug developers to narrow down the number drugs that have potential value in treating or curing specific diseases or illnesses. We offer a variety of translational-based solutions that can be customized for your clinical and pre-clinical programs. All of these solutions are based on our BIOiSIMTM platform, which is a proven and validated platform for small molecules, large molecule, and viruses. Our models are built using data from thousands upon thousands of compounds across seven species, which gives them a robustness that is rare in the industry. The platform is focused on human outcomes and has at its core a translatability tool that transforms insights across species. The BIOiSIMTM platform is available before preclinical animal trials begin, which allows for earlier insights and saves on expensive outsourced experimentation.
Learn more
InSilicoTrials
InSilicoTrials.com, a web-based platform that allows users to create and simulate computational models and simulations. There are many easy-to-use tools in silico. The platform is primarily for users in the medical device and pharmaceutical industries. In silico tools for medical devices allow computational testing in different biomedical areas such as radiology, orthopedics, and cardiovascular during product development, validation, and design. The platform offers access to in-silico tools for the pharmaceutical industry, which can be used at all stages of drug discovery and development. It also covers a variety of therapeutic areas. The only cloud-platform built on crowdscience makes it easy to access validated models and reduce your R&D expenses. There is a growing list of models that can be used on a pay-per-use basis.
Learn more
Atomwise
Our AI engine transforms drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio is co-owned and owned by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. People are the key to redefining drug discovery using AI. We are committed to creating the best AI platform possible and using it to transform small-molecule drug discovery. To help drug developers achieve their goals, we have to tackle the most difficult and seemingly impossible targets. We also need to streamline the drug discovery process in order to make it more efficient. The ability to screen trillions of compounds in silica increases the chance of success. Demonstrates exceptional model accuracy, surpassing the challenge of false negatives.
Learn more
Integrations
No Integrations at this time
Company Details
Company:
Envisagenics
Year Founded:
2014
Headquarters:
United States
Website:
www.envisagenics.com/platform/
Media
Recommended Products
Our Free Plans just got better! | Auth0 by Okta
You asked, we delivered! Auth0 is excited to expand our Free and Paid plans to include more options so you can focus on building, deploying, and scaling applications without having to worry about your secuirty. Auth0 now, thank yourself later.
Product Details
Platforms
SaaS
Type of Training
Documentation
In Person
Videos
Customer Support
Phone Support
Online
SpliceCore Features and Options
SpliceCore User Reviews
Write a Review- Previous
- Next